Pricing
  1. JP-listed companies
  2. Kringle Pharma,Inc.
  3. Financials
  4. Return on equity (%)

Kringle Pharma,Inc. (4884)

Market cap
¥2.7B
P/E ratio
-2.3x
Kringel Pharma develops treatments for rare diseases like spinal cord injury and ALS using recombinant human HGF protein technology for medical institutions and pharma partners.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndReturn on equity (%) (Million JPY)YoY (%)
Sep 30, 2025-53.6+46.38%
Sep 30, 2024-36.6+3.15%
Sep 30, 2023-35.5+183.40%
Sep 30, 2022-12.5-2.34%
Sep 30, 2021-12.8+30.92%
Sep 30, 2020-9.8-88.08%
Sep 30, 2019-82.2+474.09%
Sep 30, 2018-14.3

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat